T47D/TR-1 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
T47D/S2 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (6)
- Inventor Info
Info
| Catalogue Number | 152109 |
| Antigen/Gene or Protein Targets | Oestrogen receptor |
| Parental Line | T47D |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast carcinoma |
| Model | Tumour line |
| Relevance | The T47D/S2 Cell line is the control cell line for the tamoxifen resistant T47D/TR-1 and T47D/TR-2 lines. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth. This is the control cell line for the tamoxifen resistant T47D/TR-1 and T47D/TR-2. |
| Production Details | T47D/S2 cells have been established by reduction of the serum concentration to 2% fetal calf serum, in order to enable growth inhibition with tamoxifen. |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | Phenol red free RPMI 1640 + 2% FCS + glutamax + 8µg Insulin/ml |
| Notes |
T47DS2 cells express ER alpha and progesterone receptor. Passage 151 (AL3707, AL3708) |
| Cellosaurus ID | CVCL_1D45 |
T47D/TR-2 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
T47D-182R2 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
T47D-182R1 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
References: 6 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Europe PMC ID: 25885472
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Europe PMC ID: 25706943
Thrane et al. 2014. Oncogene. :. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Europe PMC ID: 25362855
Add a reference
References: 6 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Thrane et al. 2014. Oncogene. :. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Add a reference
